naloxegol (Movantik)
Jump to navigation
Jump to search
Introduction
FDA-approved Sept 2014.
Indications
- opioid-induced constipation
- number needed to treat to benefit 1 patient = 8
Dosage
Adverse effects
Mechanism of action
- peripheral mu-opioid receptor antagonist
More general terms
References
- ↑ Chey WD et al Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. N Engl J Med. June 4, 2014 http://www.nejm.org/doi/full/10.1056/NEJMoa1310246
- ↑ FDA News Release. September 16, 2014 FDA approves Movantik for opioid-induced constipation http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm414620.htm
- ↑ Chey WD, Webster L, Sostek M et al Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014 Jun 19;370(25):2387-96. Epub 2014 Jun 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24896818